Week of Mar 26th-30th, 2018
Check back often for weekly updates
INTERNAL GRANT OPPORTUNITIES
Internal Funding Opportunities & Limited Submission Grants:
A. Alfred Taubman Medical Research Institute – Innovation Programs: Phenotyping in the Clinical Setting (Award amount variable, rolling deadline).
The Taubman Institute is seeking to support new or existing teams of scientists to develop novel and impactful approaches to integrate their research programs into the clinic setting. The goal is to perform systematic, multiscale phenotyping to gain insights into individual variation in the susceptibility, progression, course, or outcomes of disease. The institute will partner with investigators to support the development and implementation of their research programs. This will include, but not be limited to, development of a research plan, identification of research partners within and external to U-M, infrastructure and database development, support for clinician and ancillary personnel in the clinic, clinical data collection, biological specimen collection, remote data collection, initiation of research plan, and data analysis. Our goal is to make every patient a research subject, and to define the genetic, environmental, behavioral and other components of individuals that contribute to their distinct emergent property related to health and disease. The goal is to also utilize the data to stratified an individual in order apply interventions that lead to the prevention, improved treatment, or cure of disease. The institute anticipates investing up to $2.5 million per year to support the funded projects. What are the criteria for funding? Impact on improving the lives of patients; Innovation in understanding the variability in onset or progression of disease, and reasons for differential response to treatment; Potential for future funding by the NIH or other external agencies; Potential for increased reimbursement for care by insurance companies, or cost savings to the medical system; and, Enhanced interactions with basic or other science disciplines (teams). Letter of intent: Description of the proposed program. Who is going to work together and what will be their roles? Have you worked together in the past? Where do you want to perform this work? What infrastructure is needed to accomplish the goals? Who will you need to partner with to succeed? What are the present barriers to your success? What are your plans for downstream funding? Note: not all of these points must be addressed in the LOI. We seek to understand your vision for bringing science into the clinic. The main request here is for an outline of what you want to do and why it will be impactful. There is no deadline. Letters of intent are accepted on a rolling basis, and should be submitted to managing director Grace Wu (email@example.com). We encourage questions. You may contact us with written questions through Grace Wu (firstname.lastname@example.org). We’re happy to meet with individuals or teams to discuss ideas.
Limited: U-M will internally select eight (8) concepts to bring to the foundation for feedback. U-M will then put forward up to two of the eight as fuller Phase I proposals for the May 1 deadline.
The Research Program seeks to benefit humanity by supporting projects in two specific areas (1) medical research and (2) science and engineering, that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. Past grants have been awarded to major universities, independent research institutions, and medical schools to support pioneering biological and physical science research and engineering, including the development of promising new technologies, instrumentation or methodologies. Questions: For more information regarding the review process and best practices in preparing your concept paper, please direct them to Maureen Martin (734-647-6074) in Foundation Relations. Link to Foundation Relations Keck information website. Review Process & Best Practices (Med School only) Joe Piffaretti. For questions regarding the internal competition deadline or internal submission process, please direct them to Tricia Ebright at UMOR.
EXTERNAL GRANT OPPORTUNITIES
Alex’s Lemonade Stand Foundation for Childhood Cancer 2018:
- ‘A’ Award ($800,000+ award, deadline May 21st, 2018). https://www.alexslemonade.org/grants/guidelines?utm_source=ALSF+Grants+News&utm_campaign=4af691d90b-ALSF+Grant+Announcements+%3A%3A+March+2018&utm_medium=email&utm_term=0_012b150cb4-4af691d90b-63852669 The ‘A’ Award is a four-year grant designed for the early independent career scientist who wants to establish a career in pediatric oncology research. The ideal applicant has an original project that is not currently being funded. Demonstration of a future commitment to pediatric cancer investigation as well as institutional support for the career development of the investigator are critical components of a successful application. Highlights: The ‘A’ Award is a 4-year grant, with the possibility of a 5th year of funding. The Award amount is now a maximum of $200,000 per year. A career development plan should be outlined; inclusion of a mentoring plan for at least the first 1-2 years of support is strongly encouraged. All applications must be received by May 21, 2018 -11:59 PM ET.
- 2018 Reach Grants ($250,000 award, deadline May 21st, 2018). https://www.alexslemonade.org/grants/guidelines?utm_source=ALSF+Grants+News&utm_campaign=4af691d90b-ALSF+Grant+Announcements+%3A%3A+March+2018&utm_medium=email&utm_term=0_012b150cb4-4af691d90b-63852669 Reach Grants are designed to move hypothesis-driven research into the clinic. The $250,000, two year grant is intended to fund developmental therapeutic studies in the late stage of preclinical testing. A successful application will identify an unmet clinical need relevant to the care of pediatric patients with cancer and describe how the work performed will allow for the translation to the clinic within two years of completion. A plan and timeline for clinical testing and trial implementation is expected. This grant does not fund clinical trial expenses. All Reach Award applications must be received by May 21, 2018-11:59 PM ET.
Brain Tumor Funders’ Collaborative - Request for Pre-Proposals: Immunotherapy for Primary Human Brain Tumors ($750,000 award, Pre-proposal deadline May 11th, 2018). http://www.braintumorfunders.org/2018rfp.htm The Brain Tumor Funders’ Collaborative (BTFC) works to identify potential therapies for patients with primary human brain tumors to ultimately increase overall patient survival, increase progression-free patient survival and improve the quality of life of patients affected by a primary brain tumor. The current initiative is informed by a BTFC-hosted workshop and planning meetings. Our understanding of immunotherapy for human cancer has evolved significantly over the past 20 years to the point where certain types of cancer have shown meaningful and durable responses to immune-based therapies. For example, melanoma has proven to respond very well to immunotherapy, as have certain blood-borne cancers. Immunotherapy for human brain tumors, on the other hand, is proving more difficult; a better understanding of the complex dynamics among the constituents comprising the neuro-immune system, the tumor, and the brain is required. To this end, the BTFC is prepared to sponsor research on the role of the neuro-immune system in the origin and progression of the immune responses in primary human brain tumors with the hope of developing immunotherapies for treatment of these tumors in patients. This Request for Pre-proposals focuses on supporting studies on the immune responses in primary brain tumors in pediatric and/or adult human patients. The BTFC is considering supporting a small number of multi-disciplinary team-based projects. Teams should represent the requisite skills to carry out the proposed research including clinical oncology, tumor biology, neuro-immunology, computational modelling, and data science. Other areas of immunotherapy research may also be entertained such as radiation-induced brain tumors in survivors of childhood cancers who received cranio-spinal radiation for their original cancer (leukemias or medulloblastoma). The BTFC is interested in gaining a better understanding of these immune mechanisms as they apply to human brain tumors of any grade in pediatric and adult populations. Characterization across more than one tumor type, therapeutic approach, and age group are of interest. Potential areas of exploration include, but are not limited to: What is needed to make the different kind of immunotherapies efficacious for brain tumor patients? What are the differences in the immune characteristics by tumor type or grade? What are the biological factors limiting success of any given approach, such as intra-tumoral/patient heterogeneity, risks of deleterious inflammatory responses, and therapeutic indices? What are the immunological implications of progression from low-grade gliomas to high-grade gliomas? What escape mechanisms do human brain tumors use to evade immunotherapies? What insights can we gain into predictors of response to immunotherapy? What insights can we gain into predictors of adverse effects of immunotherapy treatment at a young age? How can “big data” be used to better understand the immune system in brain tumors? In what ways might immunotherapies be ineffective or detrimental to patients? Are treatment strategies impacted by the maturation and senescence of the neuro-immune system? Maximum of $250,000 for each project per year for three years. May 11, 2018: Pre-proposals due no later than 17:00 CDT (22:00 UTC).
Alzheimer’s Drug Discovery Foundation – Harrington Scholar Program ($600,000 award, Letter of Intent deadline May 25th, 2018). https://www.alzdiscovery.org/research-and-grants/funding-opportunities/harrington The ADDF-Harrington Scholar Program is designed to accelerate the translation of innovative research efforts that could treat, prevent, slow, or cure people with Alzheimer's disease. The ADDF-Harrington Scholar Program is a collaboration between the Alzheimer's Drug Discovery Foundation (ADDF) and Harrington Discovery Institute. The goal of developing new therapies will be achieved by providing award recipients with both research funding and committed project support by a team of pharmaceutical industry experts within the Harrington Discovery Institute Innovation Support Center. The Innovation Support Center's Advisory Panel is staffed by drug development experts who have held senior management positions in established pharmaceutical companies. They have significant experience in commercial drug development, have broad, established networks, and collectively span a wide range of knowledge in drug discovery and development. Funding Priorities: Novel targets are highly encouraged. Current target areas of interest include, but are not limited to: Neuroprotection; Inflammation; Vascular function; Mitochondria & metabolic function; Proteostasis; ApoE; Epigenetics; and, Synaptic activity & neurotransmitters. The ADDF-Harrington Scholar Program does not support anti-amyloid (e.g., anti-amyloid aggregation, beta-amyloid vaccines, beta- or gamma-secretase inhibitors) or cholinesterase inhibitor approaches. Drug Targets: Proposed molecular targets will be evaluated based on the strength of available evidence that links the target to the disease and demonstrates that target modulation will be disease-modifying. Examples of target criteria include: Is there human genetic evidence linking the target to the disease? Is the target expressed in disease-relevant regions of the brain (or where applicable, in the periphery) in humans and/or animal models? Are there changes in target expression or activity in human disease specimens that correlate with disease severity and cognitive functions? Does genetic and/or pharmacological manipulation of the target improve phenotype in disease-relevant in vitro (e.g. primary cultured neurons/glia or cells derived from patient iPSCs) or in vivo models? Are there direct measures of target engagement that can be used experimentally and in humans? How is the target unique or more compelling than other related targets that have been tested for the disease? In cases where there are already drugs targeting a specific receptor or pathway, what is the compelling case for a new approach to the target (e.g., positive allosteric modulator as opposed to full agonists, etc.)? Stage of Discovery: The ADDF-Harrington Scholar Program aims to support hit-to-lead optimization through Investigational New Drug (IND)-enabling studies. Priority is given to novel programs that have: Identified a lead molecule or chemical series of molecules with data on in vitro potency (including secondary screens in relevant cell models), selectivity, and toxicity; Assessed lead chemical structure of potential liabilities; Conducted in vitro ADME (absorption, distribution, metabolism, excretion) characterization (e.g. solubility, microsomal stability, Caco-2, MDCK, CYP profiling); and, Possessed novel composition of matter IP. For in vivo efficacy studies, proposals should: Demonstrate blood-brain barrier penetration in cases of CNS targets; Justify dosing regimen and route of administration with in vivo PK/PD data; and, Include measures of target engagement. The ADDF-Harrington Scholar Program does not support target discovery, assay development, or high throughput screening campaigns. Award: Up to $300,000 per year for 2 years.
Burroughs Wellcome Fund – Career Awards at the Scientific Interface ($500,000 award, Pre-proposal deadline September 5th, 2018). https://www.bwfund.org/grant-programs/interfaces-science/career-awards-scientific-interface BWF's Career Awards at the Scientific Interface (CASI) provide $500,000 over five years to bridge advanced postdoctoral training and the first three years of faculty service. These awards are open to U.S. and Canadian citizens or permanent residents as well as to U.S. temporary residents. These grants are intended to foster the early career development of researchers who have transitioned or are transitioning from undergraduate and/or graduate work in the physical/mathematical/computational sciences or engineering into postdoctoral work in the biological sciences, and who are dedicated to pursuing a career in academic research. Scientific advances such as genomics, quantitative structural biology, imaging techniques, and modeling of complex systems have created opportunities for exciting research careers at the interface between the physical/computational sciences and the biological sciences. Tackling key problems in biology will require scientists trained in areas such as chemistry, physics, applied mathematics, computer science, and engineering. Pre-proposal Deadline: September 5, 2018 by 4:00pm EDT.
Arnold and Mabel Beckman Foundation – Argyros Award in Vision Research ($500,000 award, deadline September 28th, 2018). http://www.beckman-foundation.org/programs/beckman-argyros-vision-program-information The Beckman - Argyros Award in Vision Research rewards one individual annually who has made and is continuing to make significant transformative breakthroughs in vision research; particularly through the development of an innovative technology or fundamental scientific breakthrough that has been applied to, aided and/or improved the vision sciences. One Award will be made annually. All applicants for the Award must be nominated. The Nominator must submit a statement on the importance of the work performed by the Nominee. The Nominee must submit a summary of the impact of their work as well as a research proposal for work that would be enabled by the Award. The Award consists of a research award of $400,000 to the Nominee’s laboratory, and a personal award of $100,000 paid directly to the Nominee.
Donaghue Foundation – 2018 Greater Value Portfolio Grant Program ($400,000 award, Letter of Intent deadline May 3rd, 2018). http://donaghue.org/grant-opportunities/greater-value-portfolio/ The Donaghue Foundation announces its 2018 Greater Value Portfolio grant program that will fund research projects for two years with a maximum amount of $400,000 per award for the purpose of advancing promising approaches to achieve a higher value healthcare system. The goal of this program is to test approaches and tools that organizations can readily use to improve the value of the healthcare they provide to their patients and communities.
We believe value in healthcare is achieved with uniformly high quality outcomes and favorable patient experience for the money we spend. Symptoms of poor healthcare value include high and rising healthcare costs, unwarranted variation in prices, unacceptable variation in quality, and a lack of transparency in both price and outcomes. Investigators conducting research that expect to develop actionable solutions to one or more of these symptoms of low value healthcare are encouraged to apply to the Greater Value Portfolio program. Eligible topics include research that advances promising strategies in these areas: Reduce routine treatments, tests, and screenings for patients for whom the potential harms (including financial harm) outweigh potential benefits; Provide tools to help consumers make decisions about their healthcare based on value in addition to other patient-centered factors; Promote conversations between patients with serious illnesses and their clinicians about preferences and trade-offs related to alternative treatment options; Reduce structural barriers and inefficiencies that impede improving value within systems or across healthcare settings; or, Test models of care and coverage that address current financial disincentives for systemic change (i.e., paying for current programs with future savings or paying for programs that address social determinants of health with the savings from lowering expenditures related to clinical services). Letter of intent deadline: May 3, 2018.
Crohn’s & Colitis Foundation –
- Senior Research Awards ($315,900 award, two CY 18 funding cycle Letter of Intent deadlines: May 1st and November 1st).http://www.crohnscolitisfoundation.org/science-and-professionals/research/grants-fellowships/senior-research-awards.html Objective: To provide established researchers with funds to generate sufficient preliminary data to become competitive for funds from other sources such as the National Institutes of Health (NIH). Proposal Eligibility: Proposal must be relevant to Inflammatory Bowel Disease (IBD) or Crohn's disease and/or ulcerative colitis. Only one application is allowed per applicant per submission date. Simultaneous submission of a Senior Research Award and a Training Award is not permitted. Duration of Award: One to Three Years. Senior Research Awards Costs: Total maximum award per year: $115,830 (subject to annual progress report approval). Letter of Intent: May 1st, 5:00 pm EST; November 1st, 5:00 pm EST.
- Career Development Awards ($270,000 award, two CY 18 funding cycle Letter of Intent deadlines: May 1st and November 1st).http://www.crohnscolitisfoundation.org/science-and-professionals/research/grants-fellowships/career-development-awards.html Objective: Career Development Awards are mentored awards intended to facilitate the development of individuals with research potential to prepare for a career of independent basic and/or clinical investigation in the area of inflammatory bowel disease (IBD). Proposal Eligibility: Proposal MUST be relevant to IBD (Crohn's disease and/or ulcerative colitis) and must contain a career development plan detailing a training plan, mentorship plan, and describe how receiving this award will facilitate the transition to independence.Only one application is allowed per applicant per submission date. Duration of Award: One to three years. Total maximum award per year: $90,000 (subject to annual progress report approval). Letter of Intent: May 1st, 5:00 pm EST; November 1st, 5:00 pm EST
- Research Fellowship Awards ($174,750 award, two CY 18 funding cycle Letter of Intent deadlines: May 1st and November 1st).http://www.crohnscolitisfoundation.org/science-and-professionals/research/grants-fellowships/research-fellowship-awards.html Objective: Research Fellowship Awards are intended to support individuals in the post-doctoral phase of their career, to develop skills related to basic and/or clinical investigation in the field of inflammatory bowel disease (IBD), or Crohn’s disease and ulcerative colitis. Proposal Eligibility: Proposals MUST be relevant to IBD (Crohn's Disease or ulcerative colitis) and must include a training and a mentoring plan. Only one application is allowed per applicant per submission date. Duration of Award: One to three years. Total maximum award per year: $58,250 (subject to annual progress report approval). Letter of Intent: May 1st, 5:00 pm EST; November 1st, 5:00 pm EST.
Muscular Dystrophy Association:
- Research Grants ($300,000 award, two CY 18 funding cycle Letter of Intent deadlines: June 15th and December 15th, 2018). https://www.mda.org/research/funding-opportunities Research Grants comprise the majority of MDA’s research funding awards each year. These grants are awarded to independent, established investigators to accelerate progress toward understanding and treating neuromuscular disease and total $100,000 per year for one to three years. In a very limited number of cases, awards will exceed $100,000 per year, but pre-approval is required before letter of intent submission. Applicants are strongly encouraged to submit hypothesis-driven applications on innovative research with the following elements in mind and applications should directly relate to a disease in MDA’s program. Applications should focus on accelerating therapy development for the disease(s) in question. Such projects may include: New target identification; Target validation; Screening for new therapeutic molecules that hit validated targets; and, Addressing a need of the neuromuscular research field (e.g., developing a novel animal or cell model of the disease, developing new technologies). Clinical research projects that fit the budget restraint of this program (however, clinical trials should be submitted either through the MVP program or HCTG program). MDA is also seeking applications that may result in new understanding of disease etiology and pathogenesis in neuromuscular disorders where these are not well understood. Applications will be accepted by MDA twice yearly for Research Grants. Letters of intent due June 15, 2018 and December 15, 2018.
- Development Grants ($180,000 award, two CY funding cycle Letter of Intent deadlines: June 15th and December 15th, 2018).https://www.mda.org/research/funding-opportunities MDA Development Grants are awarded to senior postdoctoral researchers on the brink of becoming independent investigators, and are intended as seed money to help launch the scientific programs of promising new neuromuscular disease researchers. Development grants total $60,000 per year, for one to three years. Applicants are strongly encouraged to submit hypothesis-driven applications on innovative research with the following elements in mind: Applications should directly relate to a disease in MDA’s program and applications should focus on accelerating therapy development for the disease(s) in question. Such projects may include: New target identification; Target validation; Screening for new therapeutic molecules that hit validated targets; and, Addressing a need of the neuromuscular research field (e.g., developing a novel animal or cell model of the disease, developing new technologies). Clinical research projects that fit the budget restraint of this program (however, clinical trials should be submitted either through the MVP program or HCTG program). MDA is also seeking applications that may result in new understanding of disease etiology and pathogenesis in neuromuscular disorders where these are not well understood. Successful applications will include a training plan which details how the applicant will receive the necessary training and mentorship to transition to an independent research career. For projects focused on ALS: MDA has partnered with Target ALS to allow successful Development Grant recipients to access Target ALS core facilities at a reduced cost. Resources available through the core facilities include human postmortem tissue, stem cell lines, and viral vector production. Please contact MDA's ALS Scientific Program Officer Amanda Haidet-Phillips for further details concerning the terms and procedures. Applications will be accepted by MDA twice yearly for Development Grants. Letters of intent due June 15, 2018 and December 15, 2018.
American Parkinson Disease Association:
- Dr. George C. Cotzias Memorial Fellowship – Academic Year 2019-2020 ($240,000 award, deadline March 12th, 2019). https://www.apdaparkinson.org/research/research-opportunities/dr-george-c-cotzias-memorial-fellowship/ Goal: To assist promising young neurologist in establishing careers in research, teaching and patient service relevant to the problems, causes, prevention, diagnosis and treatment of Parkinson’s disease and related neurological movement disorders. Funding Disbursement: The funds ($80,000 per year) will be awarded as follows: $20,000 awarded on or about September, December, March and June of each fiscal year. Funding is subordinate to receipt of acceptable 12-month scientific and financial reports. A final scientific and financial report is also required at the end of the third year. Deadline to apply: 03/12/2019.
- Research Grants: Academic Year 2019-2020 ($50,000 award, deadline March 12th, 2019). https://www.apdaparkinson.org/research/research-opportunities/grants/APDA Research Grants are intended for scientists affiliated with U.S. research institutions. Total amount of the Research Grant will not exceed $50,000. The grant will be awarded for the duration of one (1) year. The same investigator may be supported for a maximum of two (2) consecutive years; only under exceptional conditions for three (3) consecutive years. Deadline: 03/12/2019.
American Association for Cancer Research and AstraZeneca – Stimulating Therapeutic Advancements Through Research Training (START) Grants ($225,000 award, deadline May 4th, 2018). http://www.aacr.org/Funding/Pages/Funding-Detail.aspx?ItemID=73#.Wr0bepch1PZ Dramatic advances made in recent years towards precision medicine initiatives, biomarker and novel target identification, and high-throughput examination of genomic data, have resulted in a trove of valuable data that can inform the development of new therapeutics to combat cancer. However, to effectively harness this wealth of information and advance the discovery and development of new therapies for cancer patients, enhanced collaboration between academia and industry will be needed. The AACR-AstraZeneca Stimulating Therapeutic Advancements through Research Training (START) Grants represent an exciting new initiative to encourage and support such collaboration. This novel model, which will provide support to postdoctoral or clinical research fellows, combines research experiences in both an academic and industry setting, following a research timeline that will be of greatest benefit to the proposed work. The training provided through this grants program will be invaluable to young investigators, by allowing fellows to attain a comprehensive research experience that will make them highly desirable to potential employers in either academic research or the pharmaceutical industry. Likewise, academic research centers and industry will benefit from the introduction of such dual-trained individuals into the field. Each fellowship provides a three-year grant of $225,000 to support the salary and benefits of the fellow while working on a mentored cancer research project. Applicants must plan to spend one year on site at an AstraZeneca facility. One of a number of AstraZeneca’s locations are possible, at the discretion of AstraZeneca. The year at AstraZeneca will be determined on a case-by-case basis, and will be at a time agreed upon by the fellow, the academic supervisor, the AstraZeneca mentor, and AstraZeneca. The research proposed for funding must have direct applicability to cancer with a specific focus on DNA Damage Response (DDR) pathways and may be basic, translational, or clinical in nature. Any proposals that address topics unrelated to DNA Damage Response pathways in cancer will NOT be accepted.
AACR requires applicants to submit an online application by 1:00 p.m. U.S. Eastern Time on Friday, May 4, 2018, using the proposalCENTRAL website at https://proposalcentral.altum.com.
Pfizer – 2018 US ASPIRE Investigator Research Awards in Endocrinology ($150,000 award, deadline April 27th, 2018). https://www.aspireresearch.org/endocrineglobal/index.html Pfizer is proud to introduce 2018 US ASPIRE Investigator Research Awards in Endocrinology
As competition for research funding opportunities increases, the ASPIRE program underscores Pfizer's commitment to supporting exceptional investigators with an interest in advancing their academic research careers in Endocrinology. Mission: The mission of the 2018 US ASPIRE Investigator Research Awards in Endocrinology is to advance the medical knowledge of the fundamental mechanisms of disease, mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders. The ASPIRE Program demonstrates Pfizer’s commitment to supporting exceptional investigators with an interest in advancing knowledge in defined disease areas of endocrinology. Scientific research continues to advance our knowledge and understanding of endocrine disorders and their treatments. The 2018 US ASPIRE Investigator Research Awards in Endocrinology is designed to: Support exceptional investigators working in the field of endocrinology. Advance the understanding of disease mechanisms or treatments through translational basic science or clinical research in order to enhance the clinical care of adult patients with endocrine diseases. Request for Proposals and Areas of Focus: Pfizer invites interested investigators to apply for the 2018 US ASPIRE Investigator Research Awards in Endocrinology. Funding will be provided to research proposals that seek to explore translational or clinical research in the following endocrinology areas: Acromegaly in Adults. Available Awards: Pfizer is funding 2 awards of up to $75,000 each over 2 years to conduct basic science, translational or clinical research generating data that will help advance the science of acromegaly in adults. Applications must be received by April 27, 2018 11:59pm Eastern Daylight Time.